FindTrial
Sign In

Efficacy and Safety of Low-Dose Valganciclovir for Cytomegalovirus prophylaxis and role of CMV-specific cell-mediated immunity monitoring in Kidney Transplant Recipients

Clinical outcome with low dose CMV prophylaxis and evaluation of CMV specific immunity in kidney transplant recipients - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/05/087788
Enrollment
100
Registered
2025-05-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: B259- Cytomegaloviral disease, unspecified

Interventions

Intervention1: Nil: Nil

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult Kidney transplant recipients from December 2024 to June 2026 in Nephrology department at AIIMS New Delhi

Exclusion criteria

Exclusion criteria: 1.Patients who do not give consent 2.2nd kidney transplant with previous history of CMV antigenemia

Design outcomes

Primary

MeasureTime frame
1.To study impact of low dose CMV prophylaxis on clinical outcomes in Indian kidney transplant recipients. 2. To study CMV specific immunity in Indian kidney transplant recipientsTimepoint: CMV antigenemia will be measured in all patients weekly for first 3 months after kidney transplant and CMV specific immunity will be measured using quantiferon test at the end of first month.—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDrSoumita Bagchi

All India Insititute of Medical Sciences,New Delhi

docramananads@gmail.com8281988012

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026